Ampio Pharmaceuticals (Ampio Pharmaceuticals) Growth Rank : 0 (As of May. 25, 2024)

View and export this data going back to 2003. Start your Free Trial

What is Ampio Pharmaceuticals Growth Rank?

Ampio Pharmaceuticals has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Ampio Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of Ampio Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Ampio Pharmaceuticals (Ampio Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ampio Pharmaceuticals Inc (OTCPK:AMPE) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

373 Inverness Parkway, Suite 200, Englewood, CO, USA, 80112

Website

https://www.ampiopharma.com

Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the clinical development of Ampion and preclinical development. Its product candidate, Ampion, is in clinical trials and is being developed for the treatment of severe Osteoarthritis of the Knee, an intravenous treatment for COVID-19 patients, and an inhaled treatment for COVID-19-induced respiratory distress.

Executives

J Kevin Buchi	director	41 MOORES ROAD, FRAZER PA 19355
Michael A Martino	director	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
David R Stevens	director	300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Elizabeth Varki Jobes	director	640 LEE ROAD, CHESTERBROOK PA 19087
Philip H Coelho	director	C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Holli Cherevka	officer: Chief Operating Officer	C/O AMPIO PHARMACEUTICALS, INC., 373 IVERNESS PARKWAY, ENGLEWOOD CO 80112
Dan Stokely	officer: CFO	4810 EASTGATE MALL, SAN DIEGO CA 92121
Chilcott, Iii Thomas E.	officer: Chief Financial Officer	373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Gregory A Gould	officer: Chief Financial Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Joshua R. Disbrow	officer: Chief Operating Officer	AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Michael Macaluso	director	C/O AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Richard B Giles	director	5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
David Bar-or	director, officer: Chief Scientific Officer	C/O AMPIO PHARMACEUTICALS, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
Vaughan Lennox Clift	officer: Chief Regulatory Affairs	807 NOBLE SPRINGS ROAD, HOUSTON TX 77062
Mark D Mcgregor	officer: Chief Financial Officer	5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111